Benjamin Burnett
Stock Analyst at Wells Fargo
(2.07)
# 3,019
Out of 4,996 analysts
73
Total ratings
42.31%
Success rate
-4.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Assumes: Overweight | $163 | $116.76 | +39.60% | 1 | Sep 3, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $31 | $23.26 | +33.28% | 1 | Sep 3, 2025 | |
| AVDL Avadel Pharmaceuticals | Initiates: Equal-Weight | $16 | $15.34 | +4.30% | 1 | Sep 3, 2025 | |
| ALKS Alkermes | Initiates: Overweight | $44 | $27.89 | +57.76% | 1 | Sep 3, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.00 | +200.00% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $61.67 | -20.54% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $79.69 | +53.09% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $22.97 | +200.39% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $26.83 | +153.45% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.25 | +268.00% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $13.74 | +318.49% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $5.04 | +15,376.19% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $48 | $37.98 | +26.38% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $43.92 | +45.72% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $65.55 | +43.40% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $1.69 | +136.69% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $3.51 | +184.90% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.11 | +1,084.83% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $58.50 | +515.38% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.66 | +2,309.64% | 1 | Jan 6, 2021 |
Axsome Therapeutics
Sep 3, 2025
Assumes: Overweight
Price Target: $163
Current: $116.76
Upside: +39.60%
Centessa Pharmaceuticals
Sep 3, 2025
Initiates: Overweight
Price Target: $31
Current: $23.26
Upside: +33.28%
Avadel Pharmaceuticals
Sep 3, 2025
Initiates: Equal-Weight
Price Target: $16
Current: $15.34
Upside: +4.30%
Alkermes
Sep 3, 2025
Initiates: Overweight
Price Target: $44
Current: $27.89
Upside: +57.76%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.00
Upside: +200.00%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $61.67
Upside: -20.54%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $79.69
Upside: +53.09%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $22.97
Upside: +200.39%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $26.83
Upside: +153.45%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.25
Upside: +268.00%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $13.74
Upside: +318.49%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $5.04
Upside: +15,376.19%
Sep 3, 2025
Assumes: Overweight
Price Target: $48
Current: $37.98
Upside: +26.38%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $43.92
Upside: +45.72%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $65.55
Upside: +43.40%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $1.69
Upside: +136.69%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $3.51
Upside: +184.90%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.11
Upside: +1,084.83%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $58.50
Upside: +515.38%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.66
Upside: +2,309.64%